Seer Inc. (NASDAQ: SEER) filed a patent infringement lawsuit against Nanomics Biotechnology Co., Ltd., alleging violations of five U.S. patents related to nanoparticle protein enrichment technology. Brigham and Women's Hospital joined the lawsuit as a co-plaintiff.

The asserted patents include U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect intellectual property in nanoparticle protein enrichment technology used in Seer's Proteograph Product Suite.

According to the company's statement, Nanomics allegedly infringes the patents through manufacturing, using, offering to sell, and selling its Proteonano kits and workstations. Seer seeks monetary damages and injunctive relief.

The Redwood City, California-based company maintains a patent portfolio of more than 250 patent applications and issued patents, including 84 issued patents worldwide. In March, the Patent Trial and Appeal Board upheld key claims in U.S. Patent No. 11,435,360 following an Inter Partes Review challenge.

"Our proprietary engineered nanoparticle technology is core to our solutions, and our customers demand and deserve the gold standard in proteomics technology," said Omid Farokhzad, chair and chief executive officer of Seer. "We filed this lawsuit because Seer's IP is the backbone of the entire field of protein enrichment for automated, deep, unbiased proteomics."

Seer develops proteomics technology that integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software for protein analysis research applications.